Controlled and localized release of retinoids to improve neointimal hyperplasia
US9211363B2 · kind B2 · utility
3Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2014 |
| Grant date | Dec 15, 2015 |
| Priority date | — |
| Expiry date | Nov 18, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/36
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.